• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025

    3/6/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ECOR alert in real time by email

    ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025.

    Management will host a webcast and conference call at 5:30 PM EDT to discuss the financial results and answer questions.

    Conference Call & Webcast Details

    Date: Wednesday, March 12, 2025

    Time: 5:30 PM EDT

    Registration: Click here to register to receive login credentials and dial-in details.

    About electroCore, Inc.

    electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (nVNS) technology platform. The company focuses on commercializing medical devices for managing and treating specific medical conditions, as well as consumer products utilizing nVNS to enhance general well-being and human performance in the United States and select international markets.

    For more information, visit www.electrocore.com.

    Contact:

    ECOR Investor Relations

    (973) 302-9253

    [email protected]



    Primary Logo

    Get the next $ECOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ECOR

    DatePrice TargetRatingAnalyst
    1/19/2022$3.00 → $2.75Buy
    HC Wainwright & Co.
    7/27/2021$3.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $ECOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • electroCore Announces First Quarter 2025 Financial Results

      First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. ("NeuroMetrix"); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call and webcast today, May 7, 2025 at 4:30 PM EDT ROCKAWAY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights Reported first quarter 2025 revenue of $6.7 million, a 23% increase over first quarter 2024Revenue excluding TAC-STIM totaled $

      5/7/25 4:05:00 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies

      ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the "Merger") with NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix's Quell® Fibromyalgia Solution expands electroCore's portfolio of non-invasive bioelectronic therapies, strengthens its commercial reach — particularly within the VA Hospital System — and is expected to meaningfully increase its addressable market for the treatment of chroni

      5/2/25 8:00:00 AM ET
      $ECOR
      $NURO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • electroCore's Truvaga™ Now Works with the Apple Health app

      ROCKAWAY, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its flagship wellness product, Truvaga Plus, now works with the Apple® Health app. Truvaga Plus is a hand-held vagus nerve stimulator designed to elevate the day-to-day experience through quick and gentle activation of your vagus nerve. The product is designed to provide stress relief, improve sleep, enhance peace of mind and improve focus. Danielle Jones, Sr. Director of Direct-to-Consumer Marketing at electroCore, commented, "Using Truvaga Plus with the Apple Health app on the iPhone empowers you to better manage your hea

      5/1/25 8:00:00 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on electroCore with a new price target

      HC Wainwright & Co. reiterated coverage of electroCore with a rating of Buy and set a new price target of $2.75 from $3.00 previously

      1/19/22 6:31:24 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ladenburg Thalmann initiated coverage on electroCore with a new price target

      Ladenburg Thalmann initiated coverage of electroCore with a rating of Buy and set a new price target of $3.00

      7/27/21 7:13:01 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Maxim Group resumed coverage on electroCore with a new price target

      Maxim Group resumed coverage of electroCore with a rating of Buy and set a new price target of $3.00

      3/13/21 8:17:18 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by electroCore Inc. (Amendment)

      SC 13D/A - electroCore, Inc. (0001560258) (Subject)

      6/7/24 4:33:08 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by electroCore Inc. (Amendment)

      SC 13G/A - electroCore, Inc. (0001560258) (Subject)

      2/14/24 3:15:55 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by electroCore Inc.

      SC 13D - electroCore, Inc. (0001560258) (Subject)

      12/18/23 4:10:26 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Financials

    Live finance-specific insights

    See more
    • electroCore Announces First Quarter 2025 Financial Results

      First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. ("NeuroMetrix"); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call and webcast today, May 7, 2025 at 4:30 PM EDT ROCKAWAY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights Reported first quarter 2025 revenue of $6.7 million, a 23% increase over first quarter 2024Revenue excluding TAC-STIM totaled $

      5/7/25 4:05:00 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • electroCore Announces Full Year 2024 Financial Results

      Record full year 2024 net sales of $25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCoreTM in the United States Department of Veteran Affairs and United States Department of Defense (VA) and 174% increase in TruvagaTM sales Company to host a conference call and webcast today, March 12, 2025 at 5:30pm EDT ROCKAWAY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic medicine Company and wellness company, today announced fourth quarter and full year 2024 financial results. Recent Highlights Reported record full year of 2024 revenue of $25.2 m

      3/12/25 4:05:00 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025

      ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025. Management will host a webcast and conference call at 5:30 PM EDT to discuss the financial results and answer questions. Conference Call & Webcast Details Date: Wednesday, March 12, 2025Time: 5:30 PM EDTRegistration: Click here to register to receive login credentials and dial-in details. About electroCore, Inc.electroCore, Inc. is a commercial-stage bioelectronic medicine a

      3/6/25 8:00:00 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care